🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

445 results for “SK” Clear

  1. EDP-322

    ENANTA PHARMACEUTICALS INC

    Skin and Soft Tissue Infections

    phase 1 small molecule completed

    1 trial

  2. Esketamine injection group (0.25 mg/kg)

    The First People's Hospital of Lianyungang

    Esketamine

    phase 1 small molecule active

    1 trial

  3. Faster Aspart

    Novo Nordisk A/S

    Diabetes Mellitus, Type 1

    phase 1 small molecule completed

    1 trial

  4. First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  5. First-In-Human study evaluating the Safety of administration of ABD-3001 to Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes

    Advanced Accelerator Applications

    Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes, Ineligible for Intensiveor New Generation Targeted Therapy

    phase 1 other active

    1 trial

  6. First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

    Genmab A/S

    Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

    phase 1 other active

    1 trial

  7. GSK2269557 ELLIPTA DPI

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 1 small molecule completed

    1 trial

  8. GSK2879552

    GlaxoSmithKline

    Leukaemia, Myelocytic, Acute

    phase 1 small molecule terminated

    1 trial

  9. GSK525762

    GlaxoSmithKline

    Solid Tumours

    phase 1 small molecule terminated

    1 trial

  10. GSK5533524

    GlaxoSmithKline

    Neoplasms

    phase 1 small molecule active

    1 trial

  11. GSK961081

    Theravance Biopharma Ireland Umited

    Pulmonary Disease, Chronic Obstructive

    phase 1 small molecule completed

    2 trials

  12. GSK961081 15mcg SD

    Theravance Biopharma Ireland Umited

    Pulmonary Disease, Chronic Obstructive

    phase 1 small molecule completed

    1 trial

  13. HSK3486

    The First People's Hospital of Lianyungang

    Healthy Elderly Subjects

    phase 1 small molecule completed

    1 trial

  14. HSK3486

    The First People's Hospital of Lianyungang

    Chronic Renal Impairment

    phase 1 small molecule completed

    1 trial

  15. Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer’s Disease (AD)

    IONIS PHARMACEUTICALS INC

    Alzheimer’s Disease in Individuals with Down Syndrome

    phase 1 other active

    1 trial

  16. JSP191

    Jasper Therapeutics

    Lower-risk Myelodysplastic Syndrome

    phase 1 small molecule terminated

    1 trial

  17. KB301

    Krystal Biotech Netherlands B.V.

    Skin Roughness

    phase 1 mab active

    1 trial

  18. LGH447

    Novartis Pharmaceuticals

    AML and High Risk MDS

    phase 1 small molecule completed

    1 trial

  19. NNC 0172-0000-2021

    Novo Nordisk A/S

    Congenital Bleeding Disorder

    phase 1 small molecule completed

    1 trial

  20. NNC0480-0389

    Novo Nordisk A/S

    Healthy Volunteers Type 2 Diabetes

    phase 1 small molecule completed

    1 trial

  21. Nivolumab

    Iovance Biotherapeutics B.V.

    Melanoma (Skin)

    phase 1 small molecule completed

    1 trial

  22. PD-L1/IDO Peptide Vaccine

    IO Biotech

    High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

    phase 1 mab active

    1 trial

  23. PET-imaging of two Vartumabs (F8scFv and C9scFv) in patients with solid tumors – a Phase 0 basket trial

    Lacuna Pharma Pty Ltd

    Multiple solid tumors including: colorectal carcinoma (CRC), pancreatic carcinoma, oesophageal or gastric carcinoma, head and neck squamous cell carcinoma (HNSCC), chondrosarcoma or osteosarcoma, bladder carcinoma, lung carcinoma and glioblastoma.

    phase 1 other active

    1 trial

  24. PH-762

    Phio Pharmaceuticals

    Squamous Cell Carcinoma of the Skin

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources